Physician profile
Daniel M Harada
NPI 1689787996
$7,143.77
in general payments reported to CMS, 2019-2025
29 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,410 · 2020: $1,622 · 2021: $744 · 2022: $881 · 2023: $548 · 2024: $415 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476 · Education: $11.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.80 |
| Education | $11.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,178.95 | 2019-2022 | |
| Novo Nordisk INC | $1,177.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,048.78 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $796.03 | 2019-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $678.60 | 2019-2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.00 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $290.68 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $280.09 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $183.34 | 2019-2023 | |
| Astellas Pharma US INC | $162.16 | 2019 | |
| Merck Sharp & Dohme LLC | $154.62 | 2019-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Glaxosmithkline, LLC. | $134.93 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $94.84 | 2022-2025 | |
| Esperion Therapeutics, INC. | $81.91 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $57.33 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $52.33 | 2019-2020 | |
| Convatec INC. | $35.78 | 2024 | |
| Corcept Therapeutics | $25.80 | 2023 | Korlym |
| Verona Pharma, INC. | $25.62 | 2025 | Ohtuvayre |
| Ironwood Pharmaceuticals, INC | $24.67 | 2020 | |
| Genentech USA, INC. | $24.53 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.89 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.72 | 2024 | Zoryve |
| Horizon Therapeutics Plc | $20.24 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $19.03 | 2019 | |
| Allergan, INC. | $17.69 | 2019 | |
| Dexcom, INC. | $16.77 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $16.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Harada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.